Efficacy and safety of intravenous iron therapy for HCV-positive haemodialysis patients

Nephron - Clinical Practice

Volumn 100, Issue 3, 2005, Pages

  Kahraman, Serkan ^a   Yilmaz, Rahmi ^a   Genctoy, Gultekin ^a   Arici, Mustafa ^a   Altun, Bulent ^a   Erdem, Yunus ^a   Yasavul, Unal ^a   Turgan, Cetin ^a  

^a HACETTEPE UNIVERSITY   (Turkey)

Author keywords

Haemodialysis; Hepatitis C virus; Intravenous iron; Transaminases

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; FERRIC HYDROXIDE SUCROSE; FERRITIN; HEMOGLOBIN; RECOMBINANT ERYTHROPOIETIN;

ABDOMINAL PAIN; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; AMINOTRANSFERASE BLOOD LEVEL; ANGIONEUROTIC EDEMA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEMOGRAPHY; DIARRHEA; DRUG DOSE REGIMEN; FEMALE; FERRITIN BLOOD LEVEL; FOLLOW UP; HEMODIALYSIS; HEMOGLOBIN DETERMINATION; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PRURITUS; SEROLOGY;

ADULT; ALANINE TRANSAMINASE; ANEMIA; ASPARTATE AMINOTRANSFERASES; COHORT STUDIES; ERYTHROPOIETIN, RECOMBINANT; FEMALE; HEPATITIS C; HUMANS; INJECTIONS, INTRAVENOUS; IRON; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RENAL DIALYSIS;

EID: 20944435030     PISSN: 16602110     EISSN: None     Source Type: Journal    
DOI: 10.1159/000085052     Document Type: Article

References (49)

1. Looker AC, Dallmamn PR, Carrol MD, et al: Prevalence of iron deficiency in the United States. JAMA 1997;27:973-976.
2. Barth RH: Iron metabolism in end-stage renal disease. Semin Dial 1999;12:224-230.
3. National Kidney Foundation: DOQI Clinical Practice Guidelines for the Treatment of Anaemia of Chronic Renal Failure. Am J Kidney Dis 1997;30(suppl 3):192-240.
4. Feldman HI, Santanna J, Guo W, Furst H, Franklin E, Joffe M, Marcus S, Faich G: Iron administration and clinical outcomes in hemodialysis patients. J Am Soc Nephrol 2002;13:734-744.
5. Brock JH: Iron in infection, immunity, inflammation and neoplasia; in Brock JH et al (eds): Iron Metabolism in Health and Disease. Baltimore, Saunders, 1994, pp 360-382.
6. Hoen B, Kessler M, Hestin D, Mayeux D: Risk factors for bacterial infections in chronic haemodialysis adult patients: A multicentre prospective survey. Nephrol Dial Transplant 1995;10:377-381.
7. Besarab A, Kline Bolton W, Browne JK, et al: The effects of normal as compared with low haematocrit values in patients with cardiac disease who are receiving haemodialysis and epoietin. N Engl J Med 1998;339:584-591.
8. Akpolat T, Arik N, Günaydin M, Utas C, et al: Prevalence of anti-HCV among haemodialysis patients in Turkey: A multicentre study. Nephrol Dial Transplant 1995;10:479-480.
9. Fabrizi F, Locatelli F: Hepatitis C virus in the haemodialysis units: Novel insights by new techniques? Nephrol Dial Transplant 1999;14:1072-1075.
10. Naito M, Hayashi N, Hagiwara H, Katayama K, Kasahara A, Fusamoto H, Kato M, Masuzawa M, Kamada T: Serial quantitative analysis of serum hepatitis C virus RNA level in patients with acute and chronic hepatitis C. J Hepatol 1994;20:755-759.
11. Eyster ME, Fried MW, Di Bisceglie AM, Goeder JJ: Increasing hepatitis C virus RNA levels in hemophiliacs: Relationship to human immunodeficiency virus infection and liver disease. Multicenter Hemophilia Cohort Study. Blood 1994;84:1020-1023.
12. Chazouilleres O, Kim M, Combs C, Ferrell L, Bacchetti P, Roberts J, Ascher NL, Neuwald P, Wilber J, Urdea M, et al: Quantitation of hepatitis C virus RNA in liver transplant recipients. Gastroenterology 1994;106:994-999.
13. Pol S, Romeo R, Zins B, Driss F, Lebkiri B, Carnot F, Berthelot P, Brechet C: Hepatitis C virus RNA in anti-HCV-positive hemodialyzed patients: Significance and therapeutic implications. Kidney Int 1993;44:1097-1100.
14. Caramelo C, Ortiz A, Aguilera B, Porres JC, Navas S, Marriott E, Alberola ML, Alamo C, Galera A, Garron MP, et al: Liver disease patterns in hemodialysis patients with antibodies to hepatitis C virus. Am J Kidney Dis 1993;22:822-828.
15. Al Meshari K, al Ahdal M, Alfurayh O, Ali A, De Vol E, Kessie G: New insights into hepatitis C virus infection of hemodialysis patients: The implications. Am J Kidney Dis 1995;25:572-578.
16. Heathcote EJ, Keeffe EB, Lee SS, Feinman SV, Tong MJ, Reddy KR, Albert DG Jr, Witt K, Blatt LM: Re-treatment of chronic hepatitis C with consensus interferon. Hepatology 1998;27:1136-1143.
17. Fong TL, Han SH, Tsai NC, Morgan TR, Mizokami M, Qian D, Phan C, Goad K, Redeker AG: A pilot randomized, controlled trial of the effect of iron depletion on long-term response to α-interferon in patients with chronic hepatitis C. J Hepatol 1998;28:369-374.
18. Fontana RJ, Israel J, LeClair P, Banner BF, Tortorelli K, Grace N, Levine RA, Fiarman G, Thiim M, Tavill AS, Bonkovsky HL: Iron reduction before and during interferon therapy of chronic hepatitis C: Results of a multicenter, randomized, controlled trial. Hepatology 2000;31:730-736.
19. Bonkovsky HL, Banner BF, Rothman AL: Iron and chronic viral hepatitis. Hepatology 1997;25:759-768.
20. Weiss G, Werner-Felmayer G, Werner EY, et al: Iron regulates nitric oxide synthase activity by controlling nuclear transcription. J Exp Med 1994;180:969-976.
21. Kakizaki S, Takagi H, Horiguchi N, et al: Iron enhances hepatitis C virus replication in cultured human hepatocytes. Liver 2000;20:125-128.
22. Altintepe L, Kurtoglu E, Tonbul Z, Yeksan M, Yildiz A, Turk S: Lower erythropoietin and iron supplementation are required in hemodialysis patients with hepatitis C virus infection. Clin Nephrol 2004;61:347-351.
23. Fletes R, Lazarus MJ, Gage J, Chertow GM: Suspected iron dextran-related adverse drug events in hemodialysis patients. Am J Kidney Dis 2001;37:743-749.
24. Fishbane S, Ungureanu VD, Maesaka JK, et al: The safety of intravenous iron dextran in hemodialysis patients. Am J Kidney Dis 1996;28:529-534.
25. Nissenson AR, Lindsay RM, Swan S, et al: Sodium ferric gluconate complex in sucrose is safe and effective in hemodialysis patients: North American Clinical Trial. Am J Kidney Dis 1999;33:471-482.
26. Abdalla AH, Owda AK, Fedail H, et al: Influence of hepatitis C virus infection upon parenteral iron and erythropoietin responsiveness in regular haemodialysis patients. Nephron 2000;84:293-294.
27. Koken T, Serteser M, Kahraman A, Gokce C: Oxidative stress markers in hepatitis C infected hemodialysis patients. J Nephrol 2002;15:302-307.
28. Nascimento MM, Suliman ME, Bruchfeld A, Hayashi SY, Manfro RC, Qureshi AR, Pecoits-Filho R, Pachaly MA, Renner L, Stenvinkel P, Riella MC, Lindholm B: The influence of hepatitis C and iron replacement therapy on plasma pentosidine levels in haemodialysis patients. Nephrol Dial Transplant 2004;19:3112-3116.
29. Lim PS, Wei YH, Yu YL, Kho B: Enhanced oxidative stress in haemodialysis patients receiving intravenous iron therapy. Nephrol Dial Transplant 1999;14:2680-2687.
30. Tovbin D, Mazor D, Vorobiov M, Chaimovitz C, Meyerstein N: Induction of protein oxidation by intravenous iron in hemodialysis patients: Role of inflammation. Am J Kidney Dis 2002;40:1005-1012.
31. Barbaro G, Di Lorenzo G, Ribersani M, Soldini M, Giancaspro G, Bellomo G, Belloni G, Grisorio B, Barbarini G: Serum ferritin and hepatic glutathione concentrations in chronic hepatitis C patients related to the hepatitis C virus genotype. J Hepatol 1999;30:774-782.
32. Farinati F, Cardin R, De Maria N, Della Libera G, Marafin C, Lecis E, Burra P, Floreani A, Cecchetto A, Naccarato R: Iron storage, lipid peroxidation and glutathione turnover in chronic anti-HCV-positive hepatitis. J Hepatol 1995;22:449-456.
33. McCord JM: Iron, free radicals, and oxidative injury. Semin Hematol 1998;35:5-12.
34. Anderson GJ: Non-transferrin-bound iron and cellular toxicity. J Gastroenterol Hepatol 1999;14:105-108.
35. Parkkinen J, von Bonsdorff L, Peltonen S, Gronhagen-Riska C, Rosenlof K: Catalytically active iron and bacterial growth in serum of haemodialysis patients after intravenous iron-saccharate administration. Nephrol Dial Transplant 2000;15:1827-1834.
36. Beinker NK, Voigt MD, Arendse M, Smit J, Stander IA, Kirsch RE: Threshold effect of liver iron content on hepatic inflammation and fibrosis in hepatitis B and C. J Hepatol 1996;25:633-638.
37. Theurl I, Zoller H, Obrist P, Datz C, Bachmann F, Elliott RM, Weiss G: Iron regulates hepatitis C virus translation via stimulation of expression of translation initiation factor 3. J Infect Dis 2004;190:819-825.
38. Martinelli AL, Ramalho LN, Zucoloto S: Hepatic stellate cells in hepatitis C patients: Relationship with liver iron deposits and severity of liver disease. J Gastroenterol Hepatol 2004;19:91-98.
39. Piperno A, Sampietro M, D'Alba R, Roffi L, Fargion S, Parma S, Nicoli C, Corbetta N, Pozzi M, Arosio V, Boari G, Fiorelli G: Iron stores, response to α-interferon therapy, and effects of iron depletion in chronic hepatitis C. Liver 1996;16:248-254.
40. Rubin RB, Barton AL, Banner BF, Bonkovsky HL: Iron and chronic viral hepatitis: Emerging evidence for an important interaction. Dig Dis 1995;13:223-238.
41. Hayashi H, Takikawa T, Nishimura N, Yano M, Isomura T, Sakamoto N: Improvement of serum aminotransferase levels after phlebotomy in patients with chronic active hepatitis C and excess hepatic iron. Am J Gastroenterol 1994;89:986-988.
42. Van Thiel DH, Friedlander L, Molloy PJ, Kania RJ, Fagiuoli S, Wright HI, Gasbarrini A, Caraceni P: Retreatment of hepatitis C interferon non-responders with larger doses of interferon with and without phlebotomy. Hepatogastroenterology 1996;43:1557-1561.
43. Tsai NC, Zuckerman E, Han SH, Goad K, Redeker AG, Fong TL: Effect of iron depletion on long-term response to interferon-α in patients with chronic hepatitis C who previously did not respond to interferon therapy. Am J Gastroenterol 1997;92:1831-1834.
44. Di Bisceglie AM, Bonkovsky HL, Chopra S, Flamm S, Reddy RK, Grace N, Killenberg P, Hunt C, Tamburro C, Tavill AS, Ferguson R, Krawitt E, Banner B, Bacon BR: Iron reduction as an adjuvant to interferon therapy in patients with chronic hepatitis C who have previously not responded to interferon: A multicenter, prospective, randomized, controlled trial. Hepatology 2000;32:135-138.
45. Bacon BR, Tavill AS: Hemochromatosis and the iron overload syndromes; in Zakim D, Boyer TD (eds): Hepatology: A Textbook of Liver Disease. Philadelphia, Saunders, 1996, pp 1439-1472.
46. Sherman KE: Alanine aminotransferase in clinical practice. A review. Arch Intern Med 1991;151:260-265.
47. Cahen DL, van Leeuwen DJ, ten Kate FJ, Blok AP, Oosting J, Chamuleau RA: Do serum ALAT values reflect the inflammatory activity in the liver of patients with chronic viral hepatitis? Liver 1996;16:105-109.
48. Caramelo C, Ortiz A, Aguilera B, Porres JC, Navas S, Marriott E, Alberola ML, Alamo C, Galera A, Garron MP, et al: Liver disease patterns in hemodialysis patients with antibodies to hepatitis C virus. Am J Kidney Dis 1993;22:822-828.
49. Kurihara T, Saito T: Significance of parenteral iron administration for HCV-positive hemodialysis patients. Nippon Jinzo Gakkai Shi 2002;44:389-395.